Sentences with phrase «stem cell regulation in»

According to Singh, the discovery of the counteracting repression circuitry is likely key to understanding stem cell regulation in general.

Such counteracting repression circuitry may be the key to understanding stem cell regulation in general, Singh said.

Not exact matches

The study also found that in addition to its role in determining the sex of somatic cells, Sxl regulation by m6A is required to initiate germline stem cell differentiation for developing eggs.

Without this regulation, lack of Sxl expression in stem cells can result in the development of ovarian cancer.

Hematopoietic stem cells, that form mature blood cells, require a very precise amount of protein to function — and defective regulation of protein production is common in certain types of aggressive human blood cancers.

Regulations already in place in the European Union insist that stem cell therapies follow the same safety and efficacy rules as pharmaceuticals.

In the absence of any international body that would be an obvious fit to enforce international regulations on gene editing there are historical precedents — like stem cell research — for providing guidance and then leaving the specifics up to regional authorities.

But in the study being published, researchers at the Department of Cell and Molecular Biology at Karolinska Institutet present a molecular time mechanism that can help explain neuronal stem cell regulation and therefore also the occurrence of cellular diversity in the brCell and Molecular Biology at Karolinska Institutet present a molecular time mechanism that can help explain neuronal stem cell regulation and therefore also the occurrence of cellular diversity in the brcell regulation and therefore also the occurrence of cellular diversity in the brain.

Plant researchers at VIB and Ghent University discovered a new step in the complex regulation of stem cells.

«Our results with Drosophila exhibit surprising similarities in some respects to what we know about the regulation of resting phases in mammals, allowing for speculation as to whether the Hippo signaling pathway in neural stem cells functions in the same manner in both vertebrates and invertebrates,» stated the paper's first author Rouven Ding.

Despite this, «one 2009 estimate put the number of stem - cell companies based in China at around 100», says Doug Sipp, a stem - cell ethics and regulation researcher at the RIKEN Center for Developmental Biology in Kobe, Japan.

The researchers examined respondents» deference to science on a scale of 0 - 10 when it came to 14 policy issues, including child vaccinations, stem cell research, global warming, child obesity and diet, AIDS prevention, birth control education, legalizing drug use, gun control, regulation of nuclear power, animal testing, and teaching evolution in schools.

Thorough study of changes in the gene activity regulation mechanism showed that reprogrammed and embryonic stem cells are similar.

Fiona Doetsch's group uncovered that the choroid plexus secretes a wide variety of important signaling factors in the CSF, which are important for stem cell regulation throughout life.

A group of researchers from the Centre for Genomic Regulation in Barcelona have discovered a faster and more efficient mechanism for reprogramming induced pluripotent stem cells (iPS).

The sequencing and statistical techniques the team developed can also be used by others studying regulation of stem cells in other tissues, organ systems or organisms, he said.

The experiments will also represent the first clinical trials of ES cells under regulations that China adopted in 2015, in an attempt to ensure the ethical and safe use of stem cells in the clinic.

Cohesins are protein complexes that bind two straps of DNA and are implicated in its repair, replication and recombination, as well as in its chromosomal stability, transcription regulation, stem - cell pluripotency, and cell differentiation.

Asst Prof Li, from the Neural Stem Cells Laboratory at NNI, added, «This important study suggests a link between a key neurological disease gene and regulation of microRNAs in the brain.

A Novel Role for CAMKK1 in the Regulation of the Mesenchymal Stem Cell Secretome.

Arantes - Oliveira N, Apfeld J, Dillin A, Kenyon C. Regulation of Lifespan by germ - line stem - cells in Caenorhabditis elegans.

Review of «A Novel Role for CAMKK1 in the Regulation of the Mesenchymal Stem Cell Secretome» from STEM CELLS Translational Medicine by Stuart P. AtkiStem Cell Secretome» from STEM CELLS Translational Medicine by Stuart P. AtkiSTEM CELLS Translational Medicine by Stuart P. Atkinson

In 2016, the group of Prof. Zeißig proved the decisive role of gut bacteria in the regulation of intestinal stem cells and the development of colon canceIn 2016, the group of Prof. Zeißig proved the decisive role of gut bacteria in the regulation of intestinal stem cells and the development of colon cancein the regulation of intestinal stem cells and the development of colon cancer.

Debojyoti Chakraborty (Buchholz, TUD)-- «Systematic dissection of long non coding RNAs involved in the regulation of embryonic stem cell pluripotency» (2014)

Arikawa T, Omura K, Morita I. Regulation of bone morphogenetic protein - 2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells.

In particular, we are interested in the role of transcription factor interactions for the regulation of pluripotentcy in embryonic (ES) and induced pluripotent stem (iPS) cellIn particular, we are interested in the role of transcription factor interactions for the regulation of pluripotentcy in embryonic (ES) and induced pluripotent stem (iPS) cellin the role of transcription factor interactions for the regulation of pluripotentcy in embryonic (ES) and induced pluripotent stem (iPS) cellin embryonic (ES) and induced pluripotent stem (iPS) cells.

In some countries, this phenomenon traditionally has been called stem cell tourism because it involved travel to another country with less stringent regulations to obtain treatment.

Critical issues include: (i) heterogeneity in stem cell populations (ii) regulation of cell fate choices; (iii) declining tissue performance with age and exposure to environmental injuries; (iv) the use of iPS and Embryonic Stem (ES) cells, and reprogramming methods for phenotyping disease states and potential use of these stem cells in the clistem cell populations (ii) regulation of cell fate choices; (iii) declining tissue performance with age and exposure to environmental injuries; (iv) the use of iPS and Embryonic Stem (ES) cells, and reprogramming methods for phenotyping disease states and potential use of these stem cells in the cliStem (ES) cells, and reprogramming methods for phenotyping disease states and potential use of these stem cells in the clistem cells in the clinic.

Role of the mammalian A1kB homologs 1 and 3 in RNA repair and epigenetic regulation of stem cell differentiation and development

Other bodies, such as GTAC and the MHRA, will then be involved in the regulation of any clinical trials involving either embryonic or fetal stem cells.»

Dr. Giuseppe Testa has expertise in the fields of genome engineering, stem cells and chromatin regulation, in which he pioneered new DNA engineering technologies and the characterization of new histone modifiers.

He is also interested in understanding the transcriptional regulation of lineage choice between different stem cell populations that occurs in the blastocyst.

He studies post-transcriptional regulations during oocyte - to - zygote transition and the role of small RNAs in embryonic stem cells.

The International Society for Stem Cell Research has responded the recent statement from the FDA regarding stem cell treatments, commending them for their efforts on enforcement and «appropriate oversight» in policy direction for the regulation of stem cell treatments and regenerative medicStem Cell Research has responded the recent statement from the FDA regarding stem cell treatments, commending them for their efforts on enforcement and «appropriate oversight» in policy direction for the regulation of stem cell treatments and regenerative medicCell Research has responded the recent statement from the FDA regarding stem cell treatments, commending them for their efforts on enforcement and «appropriate oversight» in policy direction for the regulation of stem cell treatments and regenerative medicstem cell treatments, commending them for their efforts on enforcement and «appropriate oversight» in policy direction for the regulation of stem cell treatments and regenerative mediccell treatments, commending them for their efforts on enforcement and «appropriate oversight» in policy direction for the regulation of stem cell treatments and regenerative medicstem cell treatments and regenerative mediccell treatments and regenerative medicine.

You are correct that stem cells are regulated by the Center for Biologics Evaluation and Research (CBER) as human cells, tissues and cellular and tissue - based products (HCT / Ps) under the authority of Section 361 of the Public Health Service (PHS) Act, and the implementing regulations in Title 21 of the Code of Federal Regulations (CFR) Part 1271 (see http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/RegulationofTissues/ucm150485.htm and http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/QuestionsaboutTissues/ucm136323.htm for more inregulations in Title 21 of the Code of Federal Regulations (CFR) Part 1271 (see http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/RegulationofTissues/ucm150485.htm and http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/QuestionsaboutTissues/ucm136323.htm for more inRegulations (CFR) Part 1271 (see http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/RegulationofTissues/ucm150485.htm and http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/QuestionsaboutTissues/ucm136323.htm for more information).

A new study from the labs of Yiqun Yu and Hongmeng Yu (Fudan University, Shanghai, China) sought to uncover the role of Notch signaling in the regulation of olfactory epithelium (OE) progenitor / stem cells.

Recently, the epidermal cells in the Arabidopsis shoot stem cell niche were quantified to assess cell size regulation triggering cytokinesis.

And David Brindley is founder and academic director of CASMI's Translational Stem Cell Consortium, senior healthcare translation research fellow in the medical sciences division's department of paediatrics at the University of Oxford, Cooksey - Saïd fellow in healthcare translation at the University of Oxford's Saïd Business School, honorary senior research associate at the University College London School of Pharmacy's Centre for Behavioral Medicine (London, UK), a research fellow in cell therapy commercialization at the Harvard Stem Cell Institute (Cambridge, MA), and regenerative medicine regulation and risk management lead at the USCF - Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) in Stanford,Cell Consortium, senior healthcare translation research fellow in the medical sciences division's department of paediatrics at the University of Oxford, Cooksey - Saïd fellow in healthcare translation at the University of Oxford's Saïd Business School, honorary senior research associate at the University College London School of Pharmacy's Centre for Behavioral Medicine (London, UK), a research fellow in cell therapy commercialization at the Harvard Stem Cell Institute (Cambridge, MA), and regenerative medicine regulation and risk management lead at the USCF - Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) in Stanford,cell therapy commercialization at the Harvard Stem Cell Institute (Cambridge, MA), and regenerative medicine regulation and risk management lead at the USCF - Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) in Stanford,Cell Institute (Cambridge, MA), and regenerative medicine regulation and risk management lead at the USCF - Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) in Stanford, CA.

An October 2006 report in the New England Journal of Medicine analyzed the FDA's updated regulation of stem - cell - based therapies.

The latest study, published in Cell Stem Cell, offers a third way to turn skin cells into stem cells by directly manipulating the cells» genome using CRISPR gene regulation techniqStem Cell, offers a third way to turn skin cells into stem cells by directly manipulating the cells» genome using CRISPR gene regulation techniqstem cells by directly manipulating the cells» genome using CRISPR gene regulation techniques.

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trRegulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trRegulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trRegulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trregulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trregulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trregulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trregulation of expression and function of the ATP - binding cassette (ABC) transporters

More important, the deposit to the Stem Cell Bank is the bellwether of many more stem cell lines to come, both from the UK licenses and, presumably, from researchers in other countries operating under their respective regulatiStem Cell Bank is the bellwether of many more stem cell lines to come, both from the UK licenses and, presumably, from researchers in other countries operating under their respective regulatiCell Bank is the bellwether of many more stem cell lines to come, both from the UK licenses and, presumably, from researchers in other countries operating under their respective regulatistem cell lines to come, both from the UK licenses and, presumably, from researchers in other countries operating under their respective regulaticell lines to come, both from the UK licenses and, presumably, from researchers in other countries operating under their respective regulations.

Human NIAM is involved in chromosome segregation, p53 regulation and cell proliferation in somatic cells, but its role in embryonic stem cells is unknown.

Rune Ougland Role of the mammalian AlkB homologs 1 and 3 in RNA repair and epigenetic regulation of stem cell differentiation and development Faculty of Medicine, University of Oslo, 29 March 2012 Supervisor: Arne Klungland

PKA and p38 MAPK signaling have not generally been explored in regulation of stem cell pluripotency or self - renewal.